CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Gastrointestinal Cancers » Colorectal Cancer

DiagnosticImaging.com.
 

CT Colonography Equal to Optical Colonoscopy, says Study

By Deborah Abrams Kaplan | May 4, 2011

CT colonography is a better screening test than optical colonoscopy (OC), according to a new study published in the MayRadiology print issue. Using meta-analysis of studies done over a 15 year period, authors found that the sensitivity of CT colonography for colorectal cancer detection was 96.1 percent, compared with 94.7 percent for OC.

Authors noted that their study supported the clinical equivalence of CTC and OC for screening invasive cancers. They felt the CTC was mature enough to be seen as a universal procedure.

(MORE: Adding CT Colonography to HEDIS Could Increase Screening Compliance)

Aside from the sensitivity rates being roughly equal, there are other reasons that the CTC can be better for screening, including cost and the minimal invasiveness. One potential downside, however, is that CTC exposes the patient to radiation, though lead author Perry J. Pickhardt, MD, a professor of radiology at the University of Wisconsin School of Medicine doesn’t think the amount is concerning. “CTC is a low-dose exam applied to adult patients,” he said. “There are no meaningful implications related to the radiation exposure.”

The meta-analysis ultimately included 49 studies covering 11,551 patients, done from January 1994 (the year that CT colonography was first mentioned), through 2009. All the CTC studies were for screening, to diagnose colorectal polyps and cancer, and all positive results were proven histologically. Six studies, encompassing 42 percent of the participants, focused on asymptomatic patients typical in a screening setting. The remaining 43 studies included symptomatic patients and/or a disease-enriched population.

Authors note the low prevalence of invasive colon cancer in screenings, citing a cumulative 3.6 percent rate from the meta-analysis. A total of 414 colorectal cancers were found in the studies, including 20 in the screening group (less than a 0.5 percent prevalence rate) and 394 in the disease-enriched group (almost a 6 percent prevalence rate).

As for the cost, Pickhardt says that using CTC is less expensive. “Our work has shown that CTC is considerably more cost-effective as a primary screening test compared with colonoscopy.”

One reported reason that patients are less likely to get a colonscopy is because the evacuatory and uncomfortable nature of the bowel preparation. Plus, OC requires the use of some anesthesia or medication for patient comfort. With CTC, those issues are diminished, according to Pickhardt. “CTC is much less invasive, requires no IV for sedation or pain medication, and requires no recovery time,” said Pickhardt, adding that patients don’t need a driver to take them home. “In addition, our low-volume bowel prep is much better tolerated than the typical colonoscopy preps in use.”
 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Steven Hirsh | May 15, 2011 2:53 AM EDT

Aside from the sensitivity rates being roughly equal, there are other reasons that the CTC can be better for screening, including cost and the minimal invasiveness. One potential downside, however, is that CTC exposes the patient to radiation, though lead author Perry J. Pickhardt, MD, a professor of radiology at the University of Wisconsin School of Medicine doesn't think the amount is concerning. "CTC is a low-dose exam applied to adult patients,"he said. "There are no meaningful implications related to the radiation exposure."

Where did you learn to write the English language???

Improper use of

concerning

by Perry Pickhardt | May 12, 2011 5:50 PM EDT

When a large polyp (10 mm or greater in size) is found at CTC, then colonoscopy is indicated for polypectomy. This occurs in about 5% of a typical screening population. Less than 1% of large 10-20 mm polyps will be cancerous. In our practice, colonoscopy is generally performed on the same day - without the need for a second bowel prep. For another 8% of patients a small polyp (6-9 mm) will be identified at CTC. Most of these patients opt for CTC surviellance in 3 years, although some opt for same-day polypectomy. These small polyps are essentially always benign and only a small fraction grow (slowly) at follow-up CTC. Therefore, the great majority of folks return to regular activities after their CTC, without the need for more invasive colonoscopy.

by Elaine McDonald | May 09, 2011 10:56 AM EDT

What about when a polyp is found? Does the patient then have to follow with an OC to have it removed and find it's pathology?

Related Articles

CT Colonography Screening Viable Option for Medicare Patients

CT Colonography as Accurate as Standard Colonoscopy in Seniors

CT Colonography Equal to Optical Colonoscopy, says Study

Bill Would Require Medicare to Cover Virtual Colonoscopy

ACR, CCA Urge Passage of Virtual Colonoscopy Bill

Virtual Colonoscopy Boosts Screening Rates 55 Percent

Post-processing Can Compensate for Prep in Virtual Colonoscopy

The Path of CT Colonography Reimbursement

Adding CT Colonography to HEDIS Could Increase Screening Compliance






 
RELATED CONTENT

ASCO: Cetuximab Ups Survival Over Bevacizumab in Colorectal Cancer
June 14, 2013
Colorectal Cancer Treatments and Therapy Innovations
May 22, 2013
Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
May 20, 2013
Axitinib Fails to Improve Survival in Metastatic Colorectal Cancer
May 6, 2013
A 47-Year-Old Patient With Chronic Abdominal Pain
April 26, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter


 
SEARCH MEDICA SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Colorectal Cancer
Evidence on Colorectal Cancer
Guidelines on Colorectal Cancer
Patient Education on Colorectal Cancer
Clinical Trials on Colorectal Cancer
Practical Articles on Colorectal Cancer
Research and Reviews on Colorectal Cancer
All "Colorectal Cancer" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy